Compare Hims and Hers Health Inc (HIMS) vs Newmont Corporation (NEM) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.

The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.

Newmont Corporation (NEM) trades at $89.52, down 0.2% over 24 hours, with technical indicators showing a bearish trend. The company reported strong fundamentals with Q1 2026 EPS of $2.90 beating expectations of $2.07, revenue growth to $22.67 billion in 2025, and robust cash flow from operations of $10.33 billion. Analyst sentiment remains overwhelmingly positive with 28 buy ratings and a consensus price target of $139.22, suggesting significant upside potential from current levels.

The outlook for Newmont is favorable due to strong earnings momentum, attractive valuation multiples (P/E of 11.63), and projected revenue growth to $25.0 billion in 2026. Key risks include exposure to gold price volatility, rising unit costs pressuring margins, and execution challenges in production growth. The stock presents a compelling opportunity for value-oriented investors given the disconnect between current price and analyst targets.